Company Profile
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Latest News
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed
Cathie Wood makes $20.5M bet on sliding tech stock
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
Cathie Wood buys $36.1 million of tumbling tech stock
Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.absci.com |
| Audit Risk | 4 |
| Board Risk | 8 |
| Overall Risk | 8 |
| Market Cap | 1.28B |
| Forward P/E | -12.14 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -0.82 |
| Forward EPS | -0.62 |
| Book Value | 1.11 |
| Price-to-Book | 6.83 |
| Enterprise-to-Revenue | 575.9 |
| Enterprise-to-EBITDA | -9.08 |
| Short Ratio | 4.56 |
| Earnings Date | 08/11/2026 |
| Earnings Call Date | 08/11/2026 |
| Earnings Average | -0.2 |
| Earnings Low | -0.23 |
| Earnings High | -0.16 |
| Revenue Average | 931,670 |
| Revenue Low | 0 |
| Revenue High | 2.50M |